AnalystBook Research · Company Intelligence

ARTIVION, INC.

AORTNYSE

Built from ARTIVION, INC.'s own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data

Artivion revenue rose 13.6% to $441.3M, net income turned positive, but free cash flow fell to $0.8M.

The read at a glance✓ Audited against SEC data
  • Business mix — Aortic devices and tissue productsNote
  • Revenue — Revenue rose 13.6% to $441.3MOK
  • Profitability — Net income was $9.8M vs. a lossOK
  • Cash — Free cash flow fell 92.4%Watch
  • Balance sheet — Debt down 31.6%; equity up 62.3%OK
  • Insiders — 0 buys / 55 sellsWatch
  • Accounting — Altman-Z distress; EQ safeWatch

Business

Artivion makes and distributes medical devices and implantable human tissue products used in cardiac and vascular procedures for aortic disease.

Where the revenue comes from

Fiscal 2025, as ARTIVION, INC. reports it. History and quarterly detail are in the app.

  • Products$345.8M
  • Preservation services$95.5M

Leadership changes

From ARTIVION, INC.'s own filings, the day they're filed.

  • Marshall S. Stanton · Chief Medical Officer · departureeff. 2026-03-31
  • Clinical Research · Chief Medical Officer · departureeff. 2026-03-31
  • Lance A. Berry · Chief Operating Officer · appointmenteff. 2025-08-11

Latest filings

  • 10-Q · Quarterly report2026-08-07
  • 8-K · Company announcement2026-08-06
  • 8-K · Company announcement2026-05-18
  • 8-K · Company announcement2026-05-15
  • 10-Q · Quarterly report2026-05-08
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about ARTIVION, INC., every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

See the full AORT record — start free

14-day free trial, no credit card. For research purposes only; not investment advice.